Tags

Type your tag names separated by a space and hit enter

Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Korean J Ophthalmol 2015; 29(4):226-32KJ

Abstract

PURPOSE

To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab).

METHODS

This is a retrospective study involving 32 eyes from 29 patients; 18 were cases of neovascular AMD and 14 were cases of PCV. The best-corrected visual acuity (BCVA) and central macular thickness (CMT) of spectral-domain optical coherence tomography were evaluated.

RESULTS

BCVA and CMT improved from 0.58 to 0.55 (p = 0.005) and from 404 to 321 µm (p < 0.001), respectively, after switching to aflibercept. The 14 eyes that received 6 or more aflibercept injections remained stable at 0.81 to 0.81 and 321 to 327 µm (p = 1.0, 0.29), respectively, after 3 aflibercept injections. The 10 eyes that received 3 or more bevacizumab injections after 3 or more aflibercept injections worsened, from 0.44 to 0.47 and from 332 to 346 µm (p = 0.06, 0.05), respectively. The results showed similar improvement of BCVA and CMT in neovascular AMD and PCV.

CONCLUSIONS

Aflibercept seems to be effective for improvement and maintenance of BCVA and CMT for neovascular AMD and PCV refractory to anti-VEGF. Switching from aflibercept back to bevacizumab treatment may not be a proper strategy.

Authors+Show Affiliations

Retina Center, Nune Eye Hospital, Seoul, Korea.Retina Center, Nune Eye Hospital, Seoul, Korea.Retina Center, Nune Eye Hospital, Seoul, Korea.Retina Center, Nune Eye Hospital, Seoul, Korea.Retina Center, Nune Eye Hospital, Seoul, Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26240506

Citation

Moon, Da Ru Chi, et al. "Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor." Korean Journal of Ophthalmology : KJO, vol. 29, no. 4, 2015, pp. 226-32.
Moon DRC, Lee DK, Kim SH, et al. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean J Ophthalmol. 2015;29(4):226-32.
Moon, D. R. C., Lee, D. K., Kim, S. H., You, Y. S., & Kwon, O. W. (2015). Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean Journal of Ophthalmology : KJO, 29(4), pp. 226-32. doi:10.3341/kjo.2015.29.4.226.
Moon DRC, et al. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean J Ophthalmol. 2015;29(4):226-32. PubMed PMID: 26240506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. AU - Moon,Da Ru Chi, AU - Lee,Dong Kyu, AU - Kim,Soon Hyun, AU - You,Yong Sung, AU - Kwon,Oh Woong, Y1 - 2015/07/21/ PY - 2014/10/03/received PY - 2015/01/05/accepted PY - 2015/8/5/entrez PY - 2015/8/5/pubmed PY - 2016/12/15/medline KW - Aflibercept KW - Anti-vascular endothelial growth factor KW - Bevacizumab KW - Macular degeneration KW - Polypoidal choroidal vasculopathy SP - 226 EP - 32 JF - Korean journal of ophthalmology : KJO JO - Korean J Ophthalmol VL - 29 IS - 4 N2 - PURPOSE: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). METHODS: This is a retrospective study involving 32 eyes from 29 patients; 18 were cases of neovascular AMD and 14 were cases of PCV. The best-corrected visual acuity (BCVA) and central macular thickness (CMT) of spectral-domain optical coherence tomography were evaluated. RESULTS: BCVA and CMT improved from 0.58 to 0.55 (p = 0.005) and from 404 to 321 µm (p < 0.001), respectively, after switching to aflibercept. The 14 eyes that received 6 or more aflibercept injections remained stable at 0.81 to 0.81 and 321 to 327 µm (p = 1.0, 0.29), respectively, after 3 aflibercept injections. The 10 eyes that received 3 or more bevacizumab injections after 3 or more aflibercept injections worsened, from 0.44 to 0.47 and from 332 to 346 µm (p = 0.06, 0.05), respectively. The results showed similar improvement of BCVA and CMT in neovascular AMD and PCV. CONCLUSIONS: Aflibercept seems to be effective for improvement and maintenance of BCVA and CMT for neovascular AMD and PCV refractory to anti-VEGF. Switching from aflibercept back to bevacizumab treatment may not be a proper strategy. SN - 2092-9382 UR - https://www.unboundmedicine.com/medline/citation/26240506/Aflibercept_Treatment_for_Neovascular_Age_related_Macular_Degeneration_and_Polypoidal_Choroidal_Vasculopathy_Refractory_to_Anti_vascular_Endothelial_Growth_Factor_ L2 - https://ekjo.org/DOIx.php?id=10.3341/kjo.2015.29.4.226 DB - PRIME DP - Unbound Medicine ER -